Compare Abeona Therapeutics Inc (ABEO) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs First Citizens BancShares Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while First Citizens BancShares Inc trades at $2,045.06 (market cap $23.94B). The key difference: First Citizens BancShares Inc is far larger — about 64.1× Abeona Therapeutics Inc's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FCNCA | |
|---|---|---|
Market Cap | $373.32M | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $2.20K |
52-Week Low | $4.17 | $1.64K |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
First Citizens BancShares (FCNCA) trades at $2,117.35, up 1.65% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamental health with a P/E of 12.21 and net income margin of 24.35%, supported by consecutive earnings beats including Q1 2026 EPS of $44.86 versus $39.56 expected. Recent corporate developments include the planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
The outlook remains positive given earnings momentum and analyst consensus price target of $2,320, though risks include margin pressure and credit exposure from the SVB integration. Upside potential hinges on continued execution amid a competitive banking landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
